ClinicalTrials.Veeva

Menu
D

DJL Clinical Research | Charlotte, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Methotrexate
ABT-494
Cenerimod
Enbrel
CHS-0214
CC-220
VIB7734
Afimetoran
Efavaleukin Alfa

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 33 total trials

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Enrolling
Sjogren's Syndrome
Drug: HZN-1116
Drug: Placebo

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to seve...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Cenerimod

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and v...

Active, not recruiting
Rheumatoid Arthritis
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus plac...

Active, not recruiting
Psoriatic Arthritis
Drug: Placebo
Drug: Upadacitinib

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Enrolling
Systemic Lupus Erythematosus
Drug: GLPG3667
Drug: Placebo

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Afimetoran

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

Active, not recruiting
Systemic Lupus Erythematosus
Other: Placebo
Drug: Standard-of-care treatment

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoi...

Active, not recruiting
Joint Diseases
Arthritis
Drug: Peresolimab
Drug: Placebo
Locations recently updated

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling
Ulcerative Colitis
Drug: Adalimumab
Drug: Lutikizumab Matching Placebo

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Enrolling
Rheumatoid Arthritis
Drug: SAR441566
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with...

Enrolling
Systemic Lupus Erythematosus
Drug: Methylprednisolone
Drug: Acetaminophen/Paracetamol

The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypo...

Enrolling
Systemic Lupus Erythematosus
Biological: MK-6194
Biological: Placebo

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting
Rheumatoid Arthritis
Procedure: Implant Procedure
Drug: Conventional Synthetic DMARD

Trial sponsors

AbbVie logo
Amgen logo
Celgene logo
Bristol-Myers Squibb (BMS) logo
C
Idorsia Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
M
Sanofi logo
Biogen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems